NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis $1.44 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.41▼$1.5650-Day Range$0.59▼$1.4452-Week Range$0.50▼$2.57Volume1.09 million shsAverage Volume1.02 million shsMarket Capitalization$77.57 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Eyenovia alerts: Email Address Eyenovia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside594.4% Upside$10.00 Price TargetShort InterestHealthy5.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 7 Articles This WeekInsider TradingAcquiring Shares$1 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.56) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector517th out of 936 stocksPharmaceutical Preparations Industry236th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has only been the subject of 1 research reports in the past 90 days.Read more about Eyenovia's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.36% of the outstanding shares of Eyenovia have been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 26.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYEN. Previous Next 3.0 News and Social Media Coverage News SentimentEyenovia has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Eyenovia this week, compared to 2 articles on an average week.Search Interest18 people have searched for EYEN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.10% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions.Read more about Eyenovia's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($0.56) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eyenovia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Eyenovia Stock (NASDAQ:EYEN)Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Read More EYEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYEN Stock News HeadlinesJuly 4, 2024 | insidertrades.comEyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Stuart M. Grant Buys 1,515,151 SharesJuly 25 at 2:14 AM | americanbankingnews.comFinancial Analysis: Eyenovia (NASDAQ:EYEN) & Cocrystal Pharma (NASDAQ:COCP)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 24 at 8:45 AM | americanbankingnews.comEyenovia (NASDAQ:EYEN) Given "Buy" Rating at HC WainwrightJuly 23 at 8:30 PM | markets.businessinsider.comEyenovia Collaborates With Senju Pharma For Potential Treatment For Chronic Dry EyeJuly 23 at 7:00 AM | globenewswire.comEyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye DiseaseJune 28, 2024 | globenewswire.comEyenovia Announces Pricing of $5M Registered Direct OfferingMay 23, 2024 | investorplace.comPeek Behind the Curtain: 7 Penny Stocks With Heavy Insider BuyingJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 21, 2024 | markets.businessinsider.comAll You Need to Know About Eyenovia Rating Upgrade to BuyMay 17, 2024 | msn.comEyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comEyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...May 15, 2024 | globenewswire.comEyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and ClobetasolMay 14, 2024 | globenewswire.comEyenovia to Report First Quarter 2024 Results on Wednesday, May 15thMay 12, 2024 | za.investing.comEarnings call: NovaBay reports record Avenova sales, eyes dry eye marketMay 4, 2024 | cnn.comEyenovia, Inc.April 26, 2024 | finanznachrichten.deEyenovia, Inc.: Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic SuspensionApril 25, 2024 | globenewswire.comEyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic SuspensionSee More Headlines Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EYEN CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+589.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,260,000.00 Net MarginsN/A Pretax Margin-360,488.88% Return on Equity-322.68% Return on Assets-100.51% Debt Debt-to-Equity Ratio3.72 Current Ratio0.88 Quick Ratio0.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book7.25Miscellaneous Outstanding Shares53,870,000Free Float50,046,000Market Cap$78.11 million OptionableOptionable Beta1.78 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Tsontcho Ianchulev M.D. (Age 50)M.P.H., MPH, Co-Founder & Executive Chairman Comp: $167.5kMr. Michael M. Rowe (Age 62)CEO & Director Comp: $775.47kMr. John P. Gandolfo CPA (Age 63)CFO & Secretary Comp: $578.15kMr. Bren Kern (Age 43)COO & Corporate VP Comp: $415.58kAlexander LoboInvestor ContactKey CompetitorsGossamer BioNASDAQ:GOSSDesign TherapeuticsNASDAQ:DSGN2seventy bioNASDAQ:TSVTESSA PharmaNASDAQ:EPIXAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsStuart M GrantBought 1,515,151 shares on 7/2/2024Total: $999,999.66 ($0.66/share)Vanguard Group Inc.Bought 360,924 shares on 5/10/2024Ownership: 3.514%BNP Paribas Financial MarketsBought 205,390 shares on 5/1/2024Ownership: 0.431%Stuart M GrantBought 100,000 shares on 3/28/2024Total: $98,000.00 ($0.98/share)Stuart M GrantBought 50,000 shares on 3/19/2024Total: $61,500.00 ($1.23/share)View All Insider TransactionsView All Institutional Transactions EYEN Stock Analysis - Frequently Asked Questions How have EYEN shares performed this year? Eyenovia's stock was trading at $2.08 at the start of the year. Since then, EYEN stock has decreased by 30.8% and is now trading at $1.44. View the best growth stocks for 2024 here. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The company earned $0.01 million during the quarter, compared to analysts' expectations of $1.23 million. When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX) and Trevena (TRVN). This page (NASDAQ:EYEN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYEN Stock Alerts